RedHill Biopharma releases corporate presentation outlining Talicia commercialization, late-stage pipeline progress

Reuters2026/08/03 07:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

RedHill Biopharma outlined its U.S. specialty pharma strategy focused on GI diseases, infectious diseases, oncology, led by Talicia commercialization.
FY 2025 net revenue USD 7.8 million; cash balance USD 4.1 million; gross margin 74.6%.
Equity financing capacity USD 31.7 million via an at-the-market purchase agreement, backed by a SEPA facility.
Talicia positioned as the leading branded H. pylori prescription among U.S. gastroenterologists; U.S. patent protection through 2042; QIDP exclusivity through 2027.
Pipeline priorities include opaganib in a Phase 2 combination study with Bayer’s darolutamide in prostate cancer, backed by multiple late-stage programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

RedHill Biopharma releases corporate presentation outlining Talicia commercialization, late-stage pipeline progress

You may also like

Crypto prices